PolyPid (PYPD) Q2 2024 earnings summary

Executive summary

• SHIELD II Phase 3 trial for D-PLEX100 enrolled approximately 320 patients across 50 centers globally, with interim analysis expected in Q4 2024 and top-line results anticipated in Q1 2025.

• Patient demographics in SHIELD II closely match those in the successful SHIELD I subgroup, supporting confidence in trial outcomes.

• No safety issues observed in SHIELD II to date; Data Safety Monitoring Committee recommended continuation without modifications.

• Regulatory pathway for NDA submission in the U.S. is clear, with FDA confirming SHIELD II sufficiency if successful.

• Promotion of Dalit Hazan to Deputy CEO, EVP, R&D, Clinical and Regulatory Affairs.

Financial highlights

• Cash, cash equivalents, and short-term deposits totaled $9.3 million as of June 30, 2024, excluding $8.1 million from PIPE financing closed in August.

• Research and development expenses for Q2 2024 were $4.8 million, up from $4 million in Q2 2023, driven by SHIELD II trial ramp-up.

• Net loss for Q2 2024 was $6.3 million ($1.25/share), compared to $5.8 million ($3.95/share) in Q2 2023.

• G&A and marketing/business development expenses decreased year-over-year due to cost savings initiatives.

• H1 2024 R&D expenses were $9.8 million, up from $7.8 million in H1 2023; net loss for H1 2024 was $12.7 million ($2.62/share) vs. $11.9 million ($10.85/share) in H1 2023.

Outlook and guidance

• Cash runway extended into Q1 2025, with potential for further extension into Q2 2025 if all warrants from recent financing are exercised.

• Interim analysis of SHIELD II expected in Q4 2024; top-line results anticipated in Q1 2025.

• Commercialization deals in Europe expected before data readout; ongoing discussions for broader platform partnerships.